目的探讨前列地尔脂微球注射液联合持续血浆滤过技术治疗高脂血症性胰腺炎的临床疗效。方法将78例高脂血症性胰腺炎患者随机分为对照组和观察组,各39例。在胰腺炎常规治疗基础上,对照组患者采用持续血浆滤过技术,观察组患者在对照组基础上加用前列地尔脂微球注射液,进行针对性的专科护理。结果两组患者治疗后生命体征较治疗前明显下降并趋于稳定,急性生理与慢性健康(APACHEⅡ)评分较治疗前有显著下降(P<0.05),观察组较对照组下降更明显,且从动态观察结果分析发现观察组下降更早(P<0.05)。两组患者治疗72 h后血脂肪酶及淀粉酶均较治疗前显著下降(P<0.05),且观察组在治疗早期较对照组显著改善。与对照组相比,观察组总治疗有效率显著升高(P<0.05),死亡率显著降低(P<0.05)。两组患者未见不良反应发生率明显差异(P>0.05)。结论前列地尔脂微球注射液联合持续血浆滤过技术治疗高脂血症性胰腺炎安全、有效。 Objective To investigate the clinical efficacy of alprostadil combined with continuous plasma filtration in the treatment of hyperlipidemic pancreatitis. Methods 78 cases of hyperlipidemic pancreatitis were randomly divided into control group and observation group, 39 cases each. On the basis of conventional treatment of pancreatitis, patients in the control group were treated with continuous plasma filtration. Patients in the observation group were treated with alprostadil microspheres injection on the basis of the control group, and targeted specialist nursing. Results After treatment, the vital signs in both groups were significantly decreased and stabilized. The scores of acute physiology and chronic health (APACHEⅡ) decreased significantly compared with that before treatment (P <0.05), and decreased more significantly in the observation group than in the control group Dynamic observation results showed that the observation group decreased earlier (P <0.05). After 72 h of treatment, blood lipase and amylase were significantly decreased in both groups (P <0.05), and the observation group was significantly improved at the early treatment stage compared with the control group. Compared with the control group, the observation group, the total effective rate was significantly increased (P <0.05), the mortality was significantly lower (P <0.05). Two groups of patients showed no significant difference in the incidence of adverse reactions (P> 0.05). Conclusion Alprostadil lipid microsphere injection combined with continuous plasma filtration in the treatment of hyperlipidemic pancreatitis is safe and effective.